| Trial ID: | L2226 |
| Source ID: | NCT06430125
|
| Associated Drug: |
Nicorandil 10 Mg Oral Tablet
|
| Title: |
Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes Mellitus
|
| Interventions: |
DRUG: Nicorandil 10 MG Oral Tablet
|
| Outcome Measures: |
Primary: prevention of progression of kidney disease as measured by KDIGO., Patients wii undergo clinical assesment for progression of diabetic nephropathy as measured by KDIGO at baseline and after 12 weeks, 12 weeks | Secondary: change in the serum concentrations of Kidney injury molecule 1(Kim-1)., Venous blood will be collected before treatment and after 12 week ., 12 weeks|change in the serum concentrations of Interleukin 18 (IL-18)., Venous blood will be collected before treatment and after 12 week ., 12 weeks|change in the serum concentrations of Nitric oxide (NO)., Venous blood will be collected before treatment and after 12 week ., 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Tanta University
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
46
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2023-02-28
|
| Completion Date: |
2025-02
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-28
|
| Locations: |
Tanta University, Tanta, EL Gharbia, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06430125
|
